budesonide/formoterol + formoterol
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stable Asthma
Conditions
Stable Asthma
Trial Timeline
Oct 1, 2002 → May 1, 2003
NCT ID
NCT00658255About budesonide/formoterol + formoterol
budesonide/formoterol + formoterol is a phase 2 stage product being developed by AstraZeneca for Stable Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00658255. Target conditions include Stable Asthma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00658255 | Phase 2 | Completed |
Competing Products
20 competing products in Stable Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Yuhan | Approved | 85 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Epoetin Alfa + Roxadustat | Astellas Pharma | Phase 3 | 77 |
| TRC041266 + Placebo | Torrent Pharmaceuticals | Phase 3 | 77 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| Ticagrelor + Clopidogrel + Aspirin | AstraZeneca | Phase 2 | 52 |
| Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) | AstraZeneca | Approved | 85 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| ticagrelor + clopidogrel | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| Nicorandil + Standard Treatment | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| CLR325 | Novartis | Phase 2 | 52 |
| Erenumab + Placebo | Amgen | Phase 2 | 51 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| ranolazine + placebo | Gilead Sciences | Approved | 84 |